Rep. April McClain Delaney Sells Off Shares of STERIS plc (NYSE:STE)

Posted by Wayne Rhoads on Aug 6th, 2026

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 31st.

Representative April McClain Delaney also recently made the following trade(s):

Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.
Purchased $1,001 – $15,000 in shares of BWX Technologies (NYSE:BWXT) on 7/30/2026.

STERIS Trading Up 0.1%

Shares of NYSE STE opened at $233.15 on Thursday. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $22.72 billion, a PE ratio of 29.40 and a beta of 0.91. The stock has a fifty day simple moving average of $214.04 and a 200-day simple moving average of $225.66. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44.

STERIS (NYSE:STE – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.10. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the company earned $2.34 earnings per share. The business’s quarterly revenue was up 7.3% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. On average, equities analysts forecast that STERIS plc will post 11.17 earnings per share for the current year.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be given a dividend of $0.69 per share. This is an increase from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Friday, September 4th. STERIS’s dividend payout ratio (DPR) is 31.78%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded STERIS from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Piper Sandler restated an “overweight” rating and issued a $270.00 price target on shares of STERIS in a research report on Thursday, May 21st. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. UBS Group assumed coverage on STERIS in a research note on Tuesday, July 28th. They set a “buy” rating and a $275.00 target price for the company. Finally, KeyCorp reduced their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and an average target price of $277.25.

View Our Latest Stock Analysis on STE

Institutional Trading of STERIS

Several hedge funds and other institutional investors have recently bought and sold shares of STE. Western Wealth Management LLC acquired a new stake in shares of STERIS during the first quarter worth $25,000. Elevation Wealth Partners LLC boosted its stake in STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 113 shares during the last quarter. Activest Wealth Management grew its holdings in STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 89 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in STERIS in the 4th quarter valued at about $28,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In related news, Director Richard C. Breeden sold 1,481 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the completion of the transaction, the director owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. This represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel A. Carestio sold 3,054 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $214.64, for a total transaction of $655,510.56. Following the sale, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at $13,956,107.44. This represents a 4.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,328 shares of company stock worth $1,554,051 in the last three months. Company insiders own 1.12% of the company’s stock.

More STERIS News

Here are the key news stories impacting STERIS this week:

Positive Sentiment: Earnings exceeded expectations: STERIS reported adjusted earnings of $2.59 per share, above the $2.49–$2.54 analyst consensus and up from $2.34 a year earlier. Revenue rose 7.3% year over year to approximately $1.5 billion. Steris Q1 Earnings Surpass Estimates
Positive Sentiment: Broad-based operating growth: Healthcare revenue increased 8% to $1.05 billion, Applied Sterilization Technologies revenue rose 6% to $297.6 million, and Life Sciences revenue grew 9% to $146.7 million. Constant-currency organic revenue growth was 6%.
Positive Sentiment: Growth investment supports longer-term prospects: STERIS plans to invest $600 million in a North Carolina formulated-chemistries manufacturing and distribution center to support sterilization and disinfection demand from healthcare and pharmaceutical customers. Steris to Invest in North Carolina Manufacturing Hub
Neutral Sentiment: Fiscal 2027 outlook was maintained: The company reiterated revenue growth guidance of 7% to 8% and adjusted EPS guidance of $11.10 to $11.30, broadly in line with analyst expectations. Capital expenditures are expected to increase to approximately $450 million, while free-cash-flow guidance is about $800 million.
Negative Sentiment: Near-term costs and cash-flow pressures: The North Carolina project and related restructuring are expected to generate approximately $55 million to $70 million in pretax charges over time. Operating cash flow declined to $367.1 million from $420.0 million in the prior-year quarter, while higher capital spending could weigh on near-term free cash flow.
Negative Sentiment: Insider selling may temper sentiment: Company insiders reported five open-market sales and no purchases over the past six months, although these transactions are not necessarily tied to the quarterly results.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About STERIS

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.